Projects that delivered results
Five research and development projects run with industrial partners and clinical institutes, from the probiotic strain to the finished formulation, from the human supplement to functional feed. Here you find what was done and with what result, without opening another page.
PRO-MIND
Probiotic and prebiotic solutions for the psychological well-being of people with chronic gastrointestinal disorders such as Irritable Bowel Syndrome. The aim is to reduce reliance on conventional antidepressants, which carry adverse effects and a substantial economic burden, through a natural approach based on optimised probiotic strains acting on gut health and depressive symptoms at the same time.
- Development and preclinical validation of the formulations on advanced experimental models
- Groundwork for the move to clinical studies in humans
- Comparative study of probiotics versus placebo on depressive symptoms in patients with disorders of gut-brain interaction
SmartNutriHealth2
Innovative nutraceutical products for healthy ageing, supporting gut and metabolic health while modulating the immune system. The project brings together the industrial and biotechnological expertise of its partners in an innovation ecosystem, with products designed from the outset for industrialisation on global markets.
- Development of next-generation probiotics and postbiotics
- Development of lactoferrin-derived functional ingredients
- Environmental and social impact analysis alongside the scientific work
Probiotiká
Two mixtures with distinct goals: one to reduce blood cholesterol, the other for dysmetabolism. For the first, a B. reuteri mutant with increased BSHase activity was selected; for the second, efficacy was confirmed in vivo in animals, with improved healthiness and weight gain.
- Study and characterisation of pro- and prebiotic products for the control of hypercholesterolaemia, with mixtures of microorganisms, vitamins and prebiotics
- Selection of a B. reuteri high producer of BSHase
- Development of a B. clausii mixture with Lactive and plant extracts for dysmetabolism
- Isolation of an antibiotic-resistant mutant
SCIDA
A mixture of two selected plant extracts and probiotics for IBS and atopic dermatitis, with confirmation of its antioxidant, prebiotic and anti-inflammatory properties and an assessment of stability. The project went all the way to a clinical trial with microbiome analysis, collecting enough data for scientific publication and patenting.
- Definition and optimisation of the pre- and probiotic mixture, focused on the anti-inflammatory effect
- Clinical trial with analysis of the volunteers’ gut microbiome before and after taking the product, using Illumina technology
- Formulation in sachets and capsules to assess stability over time and set up industrialisation
InnoFeed
Products based on selected, heat-inactivated (tyndallised) microorganisms, usable as a raw material with prebiotic properties for animal nutrition. The best formulation was identified by balancing efficacy and cost, and efficacy was confirmed by in vivo trials on piglets, administering the mixture in the feed.
- Optimisation of the microorganism tyndallisation processes
- Definition of the formulation on calibrated percentages of microorganisms and mannan-oligosaccharides (MOS)
- Measurement of the prebiotic index and selection of the best mixture
- In vivo trials on piglets with administration in the feed
